Gracell Biotechnologies Inc - ADR

NASDAQ:GRCL   3:59:54 PM EDT
7.28
+0.21 (+2.97%)
Products

Gracell Biotechnologies Granted FDA Orphan Drug Designation For Experimental Multiple Myeloma Therapy

Published: 11/19/2021 11:07 GMT
Gracell Biotechnologies Inc - ADR (GRCL) - Gracell Biotechnologies Granted FDA Orphan Drug Designation for Fastcar-enabled Bcma/cd19 Dual-targeting Car-t Cell Therapy Candidate Gc012f for the Treatment of Multiple Myeloma.
Gracell Biotechnologies-tech Transfer to Lonza to Support Manufacturing of Gc012f in U.S. is Currently Ongoing, With U.S. Ind Filing Targeting H1 2022.